Trial Profile
Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in HCV-infected Patients Receiving Peginterferon Alfa-2a Plus Ribavirin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2017
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 14 Oct 2014 Status changed from active, no longer recruiting to completed, according to the ClinicalTrials.gov record.
- 22 Jan 2014 Planned End Date changed from 1 Mar 2015 to 1 Aug 2014 as reported by ClinicalTrials.gov
- 22 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov